- Home
- GALT vs GRABW Comparison
GALT vs GRABW Comparison
Compare GALT & GRABW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- GRABW
- Stock Information
- Founded
- GALT 2000
- GRABW 2012
- Country
- GALT United States
- GRABW Singapore
- Employees
- GALT N/A
- GRABW 11267
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- GRABW Business Services
- Sector
- GALT Health Care
- GRABW Consumer Discretionary
- Exchange
- GALT Nasdaq
- GRABW Nasdaq
- Market Cap
- GALT 232.3M
- GRABW N/A
- IPO Year
- GALT N/A
- GRABW N/A
- Fundamental
- Price
- GALT $4.42
- GRABW $0.48
- Analyst Decision
- GALT Strong Buy
- GRABW
- Analyst Count
- GALT 3
- GRABW 0
- Target Price
- GALT $6.00
- GRABW N/A
- AVG Volume (30 Days)
- GALT 340.8K
- GRABW 54.7K
- Earning Date
- GALT 11-12-2025
- GRABW 02-21-2025
- Dividend Yield
- GALT N/A
- GRABW N/A
- EPS Growth
- GALT N/A
- GRABW N/A
- EPS
- GALT N/A
- GRABW N/A
- Revenue
- GALT N/A
- GRABW $2,686,000,000.00
- Revenue This Year
- GALT N/A
- GRABW N/A
- Revenue Next Year
- GALT N/A
- GRABW N/A
- P/E Ratio
- GALT N/A
- GRABW N/A
- Revenue Growth
- GALT N/A
- GRABW 21.65
- 52 Week Low
- GALT $0.73
- GRABW $0.15
- 52 Week High
- GALT $6.55
- GRABW $0.59
- Technical
- Relative Strength Index (RSI)
- GALT 51.85
- GRABW 56.79
- Support Level
- GALT $4.21
- GRABW $0.36
- Resistance Level
- GALT $6.55
- GRABW $0.48
- Average True Range (ATR)
- GALT 0.46
- GRABW 0.03
- MACD
- GALT -0.06
- GRABW -0.01
- Stochastic Oscillator
- GALT 18.97
- GRABW 99.29
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About GRABW Grab Holdings Limited Warrant
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.